CPC of America, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Submits 510(k) to FDA for use of its CPCA2000 non-invasive counter-pulsation system for treatment of patients with coronary artery disease. The device is intended for use on patients with angina who "are either not candidates for angioplasty or surgical intervention, or do not choose to undergo these more invasive techniques," the firm states